JP2008502592A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008502592A5 JP2008502592A5 JP2007503052A JP2007503052A JP2008502592A5 JP 2008502592 A5 JP2008502592 A5 JP 2008502592A5 JP 2007503052 A JP2007503052 A JP 2007503052A JP 2007503052 A JP2007503052 A JP 2007503052A JP 2008502592 A5 JP2008502592 A5 JP 2008502592A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- pharmaceutical composition
- annexin
- modified annexin
- thrombosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000000412 Annexin Human genes 0.000 claims 21
- 108050008874 Annexin Proteins 0.000 claims 21
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 230000027455 binding Effects 0.000 claims 7
- 229940096437 Protein S Drugs 0.000 claims 3
- 102000029301 Protein S Human genes 0.000 claims 3
- 108010066124 Protein S Proteins 0.000 claims 3
- 208000007536 Thrombosis Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 2
- 239000000539 dimer Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 210000002889 endothelial cell Anatomy 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004121 Annexin A5 Human genes 0.000 claims 1
- 108090000672 Annexin A5 Proteins 0.000 claims 1
- 206010003178 Arterial thrombosis Diseases 0.000 claims 1
- 206010008132 Cerebral thrombosis Diseases 0.000 claims 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 claims 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 206010047249 Venous thrombosis Diseases 0.000 claims 1
- 230000005779 cell damage Effects 0.000 claims 1
- 208000037887 cell injury Diseases 0.000 claims 1
- 208000002528 coronary thrombosis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 230000032696 parturition Effects 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55242804P | 2004-03-11 | 2004-03-11 | |
| US60/552,428 | 2004-03-11 | ||
| US57958904P | 2004-06-14 | 2004-06-14 | |
| US60/579,589 | 2004-06-14 | ||
| PCT/US2005/008193 WO2005086955A2 (en) | 2004-03-11 | 2005-03-10 | Modified annexin proteins and methods for preventing thrombosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012161761A Division JP2012254992A (ja) | 2004-03-11 | 2012-07-20 | 修飾アネキシンタンパク質および血栓症を防止するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008502592A JP2008502592A (ja) | 2008-01-31 |
| JP2008502592A5 true JP2008502592A5 (enExample) | 2008-03-21 |
| JP5134362B2 JP5134362B2 (ja) | 2013-01-30 |
Family
ID=34976262
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007503052A Expired - Fee Related JP5134362B2 (ja) | 2004-03-11 | 2005-03-10 | 修飾アネキシンタンパク質および血栓症を防止するための方法 |
| JP2012161761A Withdrawn JP2012254992A (ja) | 2004-03-11 | 2012-07-20 | 修飾アネキシンタンパク質および血栓症を防止するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012161761A Withdrawn JP2012254992A (ja) | 2004-03-11 | 2012-07-20 | 修飾アネキシンタンパク質および血栓症を防止するための方法 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1734983A4 (enExample) |
| JP (2) | JP5134362B2 (enExample) |
| AU (1) | AU2005221195B2 (enExample) |
| CA (1) | CA2559167A1 (enExample) |
| WO (1) | WO2005086955A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7645739B2 (en) * | 2001-02-21 | 2010-01-12 | Alavita Pharmaceuticals, Inc. | Modified annexin compositions and methods of using same |
| US7635676B2 (en) * | 2001-02-21 | 2009-12-22 | Alavita Pharmaccuticals, Inc. | Modified annexin proteins and methods for their use in organ transplantation |
| EP2328622B1 (en) | 2008-08-26 | 2014-12-17 | MosaMedix B.V. | Radiolabelled annexins |
| WO2013022328A1 (en) * | 2011-08-09 | 2013-02-14 | Uab Profarma | Derivatives of recombinant proteins, homo-multimers of granulocyte colony-stimulating factor and method of preparation thereof |
| GB2542391A (en) * | 2015-09-17 | 2017-03-22 | Annexin Pharmaceuticals Ab | Process of manufacture |
| US11357823B2 (en) * | 2019-08-30 | 2022-06-14 | Suzhou Yabao Pharmaceutical R&D Co., Ltd | Method for treating cerebral stroke |
| TW202146042A (zh) * | 2020-03-06 | 2021-12-16 | 瑞典商阿斯特捷利康公司 | 用於治療動脈和靜脈血栓形成的協同且靶向的組成物 |
| CN117897399A (zh) * | 2021-06-14 | 2024-04-16 | Inserm(法国国家健康医学研究院) | 突变的膜联蛋白a5多肽及其在治疗目的中的用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5968477A (en) * | 1994-01-24 | 1999-10-19 | Neorx Corporation | Radiolabeled annexin conjugates with hexose and a chelator |
| JP3742675B2 (ja) * | 1995-06-28 | 2006-02-08 | 東菱薬品工業株式会社 | 虚血−再灌流障害の予防および治療薬 |
| CA2331789C (en) * | 1998-07-13 | 2013-09-10 | Board Of Regents, The University Of Texas System | Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
| CN1125084C (zh) * | 1999-03-12 | 2003-10-22 | 中国科学院上海生物化学研究所 | 一种血栓靶向性溶栓融合蛋白 |
| EP1839670A3 (en) * | 2001-02-21 | 2009-11-11 | Alavita Pharmaceuticals, Inc. | Modified Annexin Proteins and their use against thrombosis |
| US20030152513A1 (en) * | 2001-09-06 | 2003-08-14 | Imetrix, Inc. | Intravascular delivery of therapeutic and imaging agents to stressed and apoptotic cells using annexin V as a targeting vector |
| WO2003103577A2 (en) * | 2002-06-06 | 2003-12-18 | Tze Chein Wun | Novel recombinant anticoagulant proteins |
| WO2004013303A2 (en) * | 2002-08-02 | 2004-02-12 | Surromed, Inc. | Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease |
-
2005
- 2005-03-10 CA CA002559167A patent/CA2559167A1/en not_active Abandoned
- 2005-03-10 AU AU2005221195A patent/AU2005221195B2/en not_active Ceased
- 2005-03-10 JP JP2007503052A patent/JP5134362B2/ja not_active Expired - Fee Related
- 2005-03-10 WO PCT/US2005/008193 patent/WO2005086955A2/en not_active Ceased
- 2005-03-10 EP EP05725390A patent/EP1734983A4/en not_active Withdrawn
-
2012
- 2012-07-20 JP JP2012161761A patent/JP2012254992A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Davison et al. | New aspects in the pathophysiology of preeclampsia | |
| Bezzerides et al. | CITED4 induces physiologic hypertrophy and promotes functional recovery after ischemic injury | |
| Pawlak et al. | Kynurenine pathway–a new link between endothelial dysfunction and carotid atherosclerosis in chronic kidney disease patients | |
| Meisner | Pathobiochemistry and clinical use of procalcitonin | |
| Gao et al. | Excessive autophagy induces the failure of trophoblast invasion and vasculature: possible relevance to the pathogenesis of preeclampsia | |
| Feld et al. | Renal lesions and proteinuria in the spontaneously hypertensive rat made normotensive by treatment | |
| Kahli et al. | Growth differentiation factor-15 (GDF-15) levels are associated with cardiac and renal injury in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass | |
| JP5959506B2 (ja) | 妊娠合併症を治療するための体外デバイスおよび方法 | |
| JP2004532817A5 (enExample) | ||
| Jones et al. | Cortisol stimulates system A amino acid transport and SNAT2 expression in a human placental cell line (BeWo) | |
| PT2111555E (pt) | Diagnóstico de pré-eclâmpsia | |
| WO2013143548A1 (en) | Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest | |
| Hansson et al. | Fetal hemoglobin in preeclampsia: a new causative factor, a tool for prediction/diagnosis and a potential target for therapy | |
| Song et al. | Plasma fibronectin levels in ischemic heart disease | |
| JP2008502592A5 (enExample) | ||
| Oludare et al. | L-arginine attenuates blood pressure and reverses the suppression of angiogenic risk factors in a rat model of preeclampsia | |
| Blann et al. | Increased platelet glycoprotein V levels in patients with coronary and peripheral atherosclerosis | |
| Cagliani et al. | Anti–interferon-α receptor 1 antibodies attenuate inflammation and organ injury following hemorrhagic shock | |
| JP2005516605A5 (enExample) | ||
| Yang et al. | Altered perlecan expression in placental development and gestational diabetes mellitus | |
| Chen et al. | High glucose alters proteoglycan expression and the glycosaminoglycan composition in placentas of women with gestational diabetes mellitus and in cultured trophoblasts | |
| Malyszko et al. | Renalase is removed by kidneys and during dialysis–excess related to CKD complications? | |
| Kato et al. | Oligohydramnios and pulmonary hypoplasia: a case in which involvement of an angiotensin II receptor antagonist was suspected | |
| Zagorski et al. | Rapid clearance of circulating haptoglobin from plasma during acute pulmonary embolism in rats results in HMOX1 up‐regulation in peripheral blood leukocytes | |
| JP2012506558A (ja) | 腎損傷および他の主要な器官を処置するための、診断用および間葉系幹細胞（多能性間質細胞）特異的な治療用のバイオマーカーとしてのｓｄｆ−１（ｃｘｃｌ１２）を使用する方法 |